News Flash: Merck confirm anti-PD-1 melanoma phase II drug trial

Anti-PD-1 Melanoma Phase II Drug Trial Report from Chicago today.  The drug company Merck, confirm that the anti-PD-1 melanoma phase II drug trial is complete and the data are very impressive.  Monotherapy with the drug has shown a major survival benefit in advanced melanoma. The drug, previously discussed in this blog, is essentially a booster […]